UBS raised the firm’s price target on BioNTech (BNTX) to $131 from $97 and keeps a Neutral rating on the shares following recent data from the company’s and Summit’s (SMMT)
UBS raised the firm’s price target on BioNTech (BNTX) to $131 from $97 and keeps a Neutral rating on the shares following recent data from the company’s and Summit’s (SMMT)
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
Jefferies העלו את דירוגם ל-BioNTech מדירוג החזקה לדירוג קנייה והעלו את מחיר היעד מ-96 דולר ל-150 דולר. הם מאמינים שלאחר התוצאות החיוביות של Summit Therapeutics עבור Ivonescimab, מוצרה של BioNTech,
Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics’ (SMMT) “encouraging” Ivonescimab data, BioNTech’s anti-VEGF-A antibody candidate BNT327 could
Summit Therapeutics announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting in Barcelona, Spain, including